A recent analyst report published by Euroz Hartleys following last week’s announcement of positive results from our BTX 1702 Phase 1b/2 clinical trial for rosacea. Read the full report Here.Analyst Seth Lizee noted:We believe the rosacea treatment universe is prime for disruption, with a gap in the market for drugs that can deliver similar efficacy without the side effects and limitations. “Overall, these results strengthen BOTs already valuable pipeline of products, led by its lead asset Sofpironium Bromide, which the company recently submitted a New Drug Application (NDA) for to the FDA (12 month review process).”
“We believe the rosacea treatment universe is prime for disruption, with a gap in the market for drugs that can deliver similar efficacy without the side effects and limitations.
“Overall, these results strengthen BOTs already valuable pipeline of products, led by its lead asset Sofpironium Bromide, which the company recently submitted a New Drug Application (NDA) for to the FDA (12 month review process).”
In addition, Botanix’s Chief Commercial Officer, Howie McKibbon was interviewed on@******tvthis week to discuss the positive results from our BTX 1702 Phase 1b/2 clinical trial for #rosacea. Watch the video
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $588.2M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.5¢ | 32.5¢ | $1.302M | 3.974M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 713153 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 215665 | 6 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |